Vaxess Technologies, a Cambridge, MA-based life sciences company developing a sustained-release vaccine patch, raised $27M in Series B funding.
The round was led by RA Capital Management with participation from MIT’s The Engine, Mission BioCapital, and Global Health Investment Corporation.
The company intends to use the funds to support its recently-launched phase 1 trial for the H1 influenza vaccine delivered by VX-103.
Led by CEO Michael Schrader, Vaxess Technologies is developing the MIMIX sustained release patch technology, an effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.
FinSMEs
03/11/2022